CRIS
Price
$1.63
Change
-$0.03 (-1.81%)
Updated
Aug 1 closing price
Capitalization
19.44M
NBY
Price
$0.59
Change
+$0.01 (+1.72%)
Updated
Aug 1 closing price
Capitalization
3.45M
Interact to see
Advertisement

CRIS vs NBY

Header iconCRIS vs NBY Comparison
Open Charts CRIS vs NBYBanner chart's image
Curis
Price$1.63
Change-$0.03 (-1.81%)
Volume$60.48K
Capitalization19.44M
NovaBay Pharmaceuticals
Price$0.59
Change+$0.01 (+1.72%)
Volume$30.89K
Capitalization3.45M
CRIS vs NBY Comparison Chart in %
Loading...
CRIS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.34B. The market cap for tickers in the group ranges from 58 to 213.98B. NONOF holds the highest valuation in this group at 213.98B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 0%. For the same Industry, the average monthly price growth was 16%, and the average quarterly price growth was 36%. MRSN experienced the highest price growth at 2,039%, while PBM experienced the biggest fall at -79%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -7%. For the same stocks of the Industry, the average monthly volume growth was 38% and the average quarterly volume growth was 123%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 83
Price Growth Rating: 57
SMR Rating: 92
Profit Risk Rating: 95
Seasonality Score: -11 (-100 ... +100)

Market Cap

The average market capitalization across the group is 11.45M. The market cap for tickers in the group ranges from 3.45M to 19.44M. CRIS holds the highest valuation in this group at 19.44M. The lowest valued company is NBY at 3.45M.

High and low price notable news

The average weekly price growth across all stocks in the group was -12%. For the same group, the average monthly price growth was -6%, and the average quarterly price growth was -32%. CRIS experienced the highest price growth at -11%, while NBY experienced the biggest fall at -12%.

Volume

The average weekly volume growth across all stocks in the group was -40%. For the same stocks of the group, the average monthly volume growth was -33% and the average quarterly volume growth was -41%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 36
P/E Growth Rating: 75
Price Growth Rating: 74
SMR Rating: 56
Profit Risk Rating: 100
Seasonality Score: -50 (-100 ... +100)
VS
CRIS vs. NBY commentary
Aug 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRIS is a Hold and NBY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 02, 2025
Stock price -- (CRIS: $1.63 vs. NBY: $0.59)
Brand notoriety: CRIS and NBY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRIS: 49% vs. NBY: 86%
Market capitalization -- CRIS: $19.44M vs. NBY: $3.45M
CRIS [@Biotechnology] is valued at $19.44M. NBY’s [@Biotechnology] market capitalization is $3.45M. The market cap for tickers in the [@Biotechnology] industry ranges from $213.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRIS’s FA Score shows that 0 FA rating(s) are green whileNBY’s FA Score has 2 green FA rating(s).

  • CRIS’s FA Score: 0 green, 5 red.
  • NBY’s FA Score: 2 green, 3 red.
According to our system of comparison, NBY is a better buy in the long-term than CRIS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRIS’s TA Score shows that 3 TA indicator(s) are bullish while NBY’s TA Score has 4 bullish TA indicator(s).

  • CRIS’s TA Score: 3 bullish, 6 bearish.
  • NBY’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, NBY is a better buy in the short-term than CRIS.

Price Growth

CRIS (@Biotechnology) experienced а -11.41% price change this week, while NBY (@Biotechnology) price change was -11.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.14%. For the same industry, the average monthly price growth was +15.55%, and the average quarterly price growth was +36.18%.

Reported Earning Dates

CRIS is expected to report earnings on May 06, 2025.

NBY is expected to report earnings on May 15, 2025.

Industries' Descriptions

@Biotechnology (+0.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRIS($19.4M) has a higher market cap than NBY($3.45M). NBY YTD gains are higher at: -1.248 vs. CRIS (-46.732). NBY has higher annual earnings (EBITDA): -6.8M vs. CRIS (-40.26M). CRIS has more cash in the bank: 20.3M vs. NBY (8.47M). NBY has less debt than CRIS: NBY (1.13M) vs CRIS (2.64M). CRIS has higher revenues than NBY: CRIS (11.2M) vs NBY (9.78M).
CRISNBYCRIS / NBY
Capitalization19.4M3.45M562%
EBITDA-40.26M-6.8M592%
Gain YTD-46.732-1.2483,745%
P/E RatioN/A0.02-
Revenue11.2M9.78M115%
Total Cash20.3M8.47M240%
Total Debt2.64M1.13M235%
FUNDAMENTALS RATINGS
CRIS vs NBY: Fundamental Ratings
CRIS
NBY
OUTLOOK RATING
1..100
5158
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
13
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10012
PRICE GROWTH RATING
1..100
9554
P/E GROWTH RATING
1..100
10050
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NBY's Valuation (13) in the Biotechnology industry is somewhat better than the same rating for CRIS (60). This means that NBY’s stock grew somewhat faster than CRIS’s over the last 12 months.

NBY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRIS (100). This means that NBY’s stock grew similarly to CRIS’s over the last 12 months.

NBY's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for CRIS (100). This means that NBY’s stock grew significantly faster than CRIS’s over the last 12 months.

NBY's Price Growth Rating (54) in the Biotechnology industry is somewhat better than the same rating for CRIS (95). This means that NBY’s stock grew somewhat faster than CRIS’s over the last 12 months.

NBY's P/E Growth Rating (50) in the Biotechnology industry is somewhat better than the same rating for CRIS (100). This means that NBY’s stock grew somewhat faster than CRIS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRISNBY
RSI
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
N/A
Bullish Trend 15 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
CRIS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
JFU1.640.02
+1.23%
9F
SNDX9.980.06
+0.60%
Syndax Pharmaceuticals
HFFG2.67-0.04
-1.48%
HF Foods Group
DVN32.14-1.08
-3.25%
Devon Energy Corp
CVI25.06-3.21
-11.35%
CVR Energy

CRIS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CRIS has been loosely correlated with ABEO. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CRIS jumps, then ABEO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRIS
1D Price
Change %
CRIS100%
-1.81%
ABEO - CRIS
37%
Loosely correlated
+1.88%
ROIV - CRIS
36%
Loosely correlated
-0.79%
CGON - CRIS
36%
Loosely correlated
-1.42%
ORMP - CRIS
34%
Loosely correlated
-1.40%
OBIO - CRIS
34%
Loosely correlated
-20.26%
More

NBY and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NBY has been loosely correlated with PRTG. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if NBY jumps, then PRTG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBY
1D Price
Change %
NBY100%
+2.15%
PRTG - NBY
38%
Loosely correlated
-9.06%
ALT - NBY
30%
Poorly correlated
-2.17%
ORMP - NBY
29%
Poorly correlated
-1.40%
IMMP - NBY
25%
Poorly correlated
-1.15%
PMN - NBY
25%
Poorly correlated
-0.60%
More